Original articleClinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders☆
Introduction
The pharmacological armamentarium for treatment of bipolar illness has expanded to encompass a large array of potential therapeutic agents Gelenberg and Hopkins 1993, McElroy and Keck 2000, Post et al 1998, Post 2000, Sachs and Thase 2000, Thase and Sachs 2000, making efforts to identify responsive categories and subtypes of bipolar disorder, as well as delineating clinical and biological markers of response, particularly important. The mood stabilizers lithium, valproate, and carbamazepine have partially overlapping as well as different mechanisms of action (Post et al 2000). Each has preliminarily been associated with different spectra of clinical efficacy and adverse effects Bowden 1995, Calabrese et al 1996a, Denicoff et al 1997, Swann et al 1999.
Bipolar modifiers or subtypes that are poorly responsive to lithium include the following: dysphoric mania Himmelhoch and Garfinkel 1986, Swann et al 1997; rapid cycling (Dunner and Fieve 1974); the depression-mania-well interval sequence (Faedda et al 1991); substance abuse comorbidity (O’Connell et al 1991); lack of family history of bipolar illness and noncompliance or discontinuation (Denicoff et al 1997). Valproate has shown efficacy in the treatment of some lithium refractory patients, such as those with rapid cycling (Calabrese and Woyshville 1995) and mixed states Bowden et al 1994, McElroy et al 1992, Swann et al 1997 . Correlates of better response to valproate include those with electroencephalogram abnormalities (McElroy et al 1987, but not subsequently replicated by the same group) and less cycle acceleration Calabrese et al 1993a, Calabrese et al 1993b. Subgroups of patients who show improvement during treatment with carbamazepine include those with greater initial depression severity and less chronicity (Post et al 1986); less rapid cycling Denicoff et al 1997, Okuma 1993; and atypical presentations with comorbidities and schizoaffective characteristics (Greil et al 1997). All three drugs appear to be more effective in acute mania than acute depression.
Several of the newer anticonvulsants are being investigated for their efficacy in acute affective episodes and as putative mood stabilizers. Like several other agents (tiagabine, vigabatrin, and valproate) gabapentin increases brain levels of the major inhibitory neurotransmitter, γ-aminobutyric acid (GABA) (Taylor et al 1998). Although open uncontrolled studies suggest that gabapentin may be a useful adjunct in the treatment of some residual bipolar symptoms Altshuler et al 1999, Erfurth et al 1998, Ghaemi et al 1998, Knoll et al 1998, McElroy et al 1997, Perugi et al 1999, Sokolski et al 1999, Young et al 1999, double-blind, controlled studies have not indicated efficacy in acute mania (Pande et al 2000) or as a mood stabilizer (Frye et al 2000).
Lamotrigine, like carbamazepine and phenytoin, blocks sodium channels (Xie and Hagan 1998). Preliminary data suggest that carbamazepine and lamotrigine also reduce the calcium influx through the N-methyl-D-aspartate receptor Hough et al 1996, Stefani et al 1996. In addition, lamotrigine is reported to block Ca2+ influx through the N-type channels Stefani et al 1996, Wang et al 1996, Wang et al 1998. Open (Calabrese et al 1996b) and blind studies Calabrese et al 1999, Frye et al 2000 suggested antidepressant efficacy and perhaps positive effects of lamotrigine as a mood stabilizer.
The current study, which is an extension of Frye et al (2000), attempts to delineate some of the possible clinical correlates of response to lamotrigine or gabapentin monotherapy. We examined the proposition that differences in the phenomenology and neurobiology of affective illness would be reflected in differences in the response to these two anticonvulsants with very different putative mechanisms of action—lamotrigine (as an antiglutamatergic agent) and gabapentin (as a GABA enhancing agent).
Section snippets
Subjects
Subjects recruited to the study were 45 patients with treatment refractory bipolar (n = 35) or unipolar (n = 10) affective disorder. Thirty-eight of these patients were included in the initial report (Frye et al 2000). Patients were admitted to the Biological Psychiatry Branch of the National Institute of Mental Health (NIMH) for evaluation and treatment of their illness, which had not responded adequately to conventional agents used in the community (see Frye et al 2000 for details). All
Results
The patient population was highly treatment refractory (Table 1). Before study entry, patients in the unipolar group had an average of 2.6 prior hospitalizations. The bipolar group had an average of 4.5 hospitalizations (3.6 for depression, 0.9 for mania). Lithium had been used unsuccessfully in 91% of cases. Patients had either failed to respond or developed refractoriness in all of those cases (Post et al 1993). Valproate had been used in 80% of cases, and carbamazepine in 57%. Treatment
Discussion
There is a pressing medical need for a more rational application of older and newer therapeutic approaches in bipolar disorder, because conventional medications (i.e., lithium, carbamazepine, and valproate) fail in a substantial portion of bipolar patients, with depression representing the major problem Denicoff et al 1997, Denicoff et al 2000, Gitlin and Altshuler 1997, Goldberg 2000. Several lines of evidence suggest that lamotrigine has antidepressant properties and possible mood stabilizing
References (80)
- et al.
An open label study of gabapentin in the treatment of acute mania
J Psychiatr Res
(1998) - et al.
Changes in the gene expression of GABAA receptor subunit mRNAs in the septum of rats subjected to pentylenetetrazol-induced kindling
Brain Res Mol Brain Res
(1999) - et al.
GABA-stimulated chloride uptake during avian CNS developmentModulation by neurosteroids
Int J Dev Neurosci
(1998) - et al.
Predictors of recurrence in affective disorders—analysis accounting for individual heterogeneity
J Affect Disord
(2000) - et al.
Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania
J Affect Disord
(1998) - et al.
Tolerance to the anticonvulsant effects of lamotrigine on amygdala kindled seizuresCross-tolerance to carbamazepine but not valproate or diazepam
Exp Neurol
(2000) - et al.
Pharmacologic agents for the treatment of acute bipolar mania
Biol Psychiatry
(2000) - et al.
Gabapentin for parkinsonismA double-blind, placebo-controlled, crossover trial
Am J Med
(1997) - et al.
Beyond lithium in the treatment of bipolar illness
Neuropsychopharmacology
(1998) - et al.
Bipolar disorder therapeuticsMaintenance treatment
Biol Psychiatry
(2000)
Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression
Biol Psychiatry
Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP)The CGI-BP
Psychiatry Res
Lamotrigine inhibits Ca2+ currents in cortical neuronsFunctional implications
Eur J Pharmacol
Sex and age differences of neurons expressing GABA-immunoreactivity in the rat bed nucleus of the stria terminalis
Int J Dev Neurosci
A summary of mechanistic hypotheses of gabapentin pharmacology
Epilepsy Res
Bipolar depressionPharmacotherapy and related therapeutic strategies
Biol Psychiatry
Gabapentin in the acute treatment of refractory bipolar disorder
Bipolar Disord
Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromesA pilot study
Eur Neurol
Predictors of response to divalproex and lithium
J Clin Psychiatry
Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group
JAMA
Methods for reliable longitudinal observation of behavior
Arch Gen Psychiatry
A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group
J Clin Psychiatry
Predictors of response to mood stabilizers
J Clin Psychopharmacol
Antidepressant effects of lamotrigine in rapid cycling bipolar disorder
Am J Psychiatry
Rapid cycling bipolar disorder and its treatment with valproate
Can J Psychiatry
Clinical studies on the use of lamotrigine in bipolar disorder
Neuropsychobiology
A double-blind placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group
J Clin Psychiatry
A medication algorithm for treatment of bipolar rapid cycling?
J Clin Psychiatry
Predictors of valproate response in bipolar rapid cycling
J Clin Psychopharmacol
Gabapentin and motor fluctuations in Parkinson’s disease
Mov Disord
Morbidity in 202 patients followed for one year in the Stanley Foundation Bipolar Network (SFBN)
Presented at the Second European Stanley Foundation Conference on Bipolar Disorder
Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder
J Clin Psychiatry
Clinical factors in lithium carbonate prophylaxis failure
Arch Gen Psychiatry
Episode sequence in bipolar disorder and response to lithium treatment
Am J Psychiatry
Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (Research Version, 2/96 final)
Statistical Methods for Rates and Proportions
A placebo controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders
J Clin Psychopharmacol
Report on efficacy of treatments for bipolar disorder
Psychopharmacol Bull
Gabapentin treatment of mood disordersA preliminary study
J Clin Psychiatry
A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor
Arch Neurol
Cited by (100)
Sex differences in effectiveness and adverse effects of mood stabilizers and antipsychotics: A systematic review
2024, Journal of Affective DisordersPersonalized treatment in bipolar disorder
2019, Personalized PsychiatrySymptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion
2017, Journal of Affective DisordersTreatment of Bipolar Depression: Evolving Recommendations
2016, Psychiatric Clinics of North AmericaCitation Excerpt :Moreover, the side effects of carbamazepine are prevented by lithium in the realm of benign suppression of the white count (because of opposite effects on colony-stimulating factor) and in the induction of hyponatremia (because of differing effects on vasopressin-like effects). The clinical predictors of response to lamotrigine are less well elucidated, but include fewer number of prior depressive episodes, a personal history of anxiety disorders, and most interestingly, positive family history of anxiety disorders and substance abuse.26,33,34 Controlled studies have indicated that the addition of lamotrigine to quetiapine,35 valproate,36 or lithium37 has greater positive effects than the addition of placebo.
Role of calcium, glutamate and NMDA in major depression and therapeutic application
2016, Progress in Neuro-Psychopharmacology and Biological PsychiatryA critical overview of the clinical evidence supporting the concept of neuroprogression in bipolar disorder
2016, Psychiatry ResearchCitation Excerpt :Similarly, a late non-response to lithium prophylaxis was shown in patients with higher number of previous episodes and hospitalizations (Maj et al., 1996). Another study reported that response to lamotrigine was negatively correlated with the number of previous episodes (Obrocea et al., 2002). A similar pattern was also observed with antipsychotic medications.
- ☆
Support of the Theodore and Vada Stanley Foundation is gratefully acknowledged